Sanofi's diabetes business affected by Q4 falling prices and Covid-19
Sanofi's diabetes business retreated in Q4 of 2020 due to decreased prices and coronavirus.
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY NIELSINE NIELSEN
French pharmaceutical company Sanofi has published its fiscal report for Q4 2020, and even though the firm reports a 4.2-percent growth in sales for the business leg over the course of the fourth quarter, the picture is less rosy in view of the diabetes business.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
.jpg&w=384&q=75)
